<DOC>
	<DOCNO>NCT00622713</DOCNO>
	<brief_summary>This study design confirm efficacy , tolerability , patient compliance caregiver satisfaction rivastigmine target patch size 10 cm^2 patient probable Alzheimer 's Disease ( Mini-Mental State Examination 10-26 ) community set</brief_summary>
	<brief_title>A 24 Week , Multicenter , Open , Evaluation Clinical Effectiveness Once-daily 10 cm^2 Rivastigmine Patch Formulation Patients With Probable Alzheimer 's Disease ( EXTRA )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Males , female least 50 year old primary caregiver Probable Alzheimer 's disease MiniMental State Examination ( MMSE ) score ≥ 10 ≤ 26 Patients initiate therapy first time Cholinesterase ( ChE ) inhibitor ( patient prescribe rivastigmine memantine allow ) patient fail benefit previous ChE inhibitor treatment Residing someone community throughout study , live alone , contact responsible caregiver everyday Patients treat accord product monograph capsule Current diagnosis active skin lesion/disorder would prevent accurate assessment adhesion potential skin irritation patch ( e.g. , atopic dermatitis , wound scratch skin area patch application ) History allergy topical product contain constituent patch Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>cholinesterase inhibitor</keyword>
	<keyword>rivastigmine</keyword>
</DOC>